Glimepiride is an oral sulfonylurea drug; nicotinamide is an inhibitor of poly (ADP-ribose) synthetase and a precursor of NAD. Your doctor may occasionally change your dose to make sure you get the best results. The importance of blood glucose control was shown in the UK Prospective Diabetes Study (UKPDS), showing that early intensive blood glucose control from the time of diagnosis of diabetes mellitus reduced micro- and macrovascular complications, as well as mortality[1-3]. Reduction was also significant (P < 0.001) in both groups in FPG (-15.49 mg and -29.84 mg respectively) and 2HPPG (-34.28 mg and -44.83 mg respectively). This meta-analysis supported that both metformin and glimepiride was effective in treating T2DM for glycemic control. Such action mechanisms might be suitable for the treatment of glucocorticoid-induced diabetes. In the subgroup of patients with coronary artery disease (CAD), glipizide and glyburide had significant associations with mortality versus metformin but not glimepiride.
Based on BMI, the mean reduction of HBA1c in 20 normal weight patients was 1.3%, and more marked in 20 obese patients (2.4%). Older age was associated with a smaller response. Significant BMI decrease was observed at 12 months in glimepiride and rosiglitazone group (p < 0.05 and p < 0.01 respectively) as well as of glycated haemoglobin decrease (p < 0.05 and p < 0.01 respectively), mean fasting plasma glucose and postprandial plasma glucose levels (p < 0.05 and p < 0.01 respectively). First and recurrent amputations were lower in the rosiglitazone group, probably due to a 'survival paradox' in the liraglutide arms (number of events: 565, 529, and 507, respectively). Overall cumulative costs per patient, were lower in both liraglutide groups compared to rosiglitazone (US$38,963, $39,239, and $40,401 for liraglutide 1.2 mg, 1.8 mg, and rosiglitazone, respectively), mainly driven by the costs of cardiovascular events in all groups. Overall, both treatments were well tolerated and displayed similar safety profiles.